Search clinical trials for: ASP8374

Total 29 results

UMN Pharma Inc.

Completed

A Study to Evaluate Intramuscular ASP7374

Influenza | Vaccine

Japan
UMN Pharma Inc.

Completed

A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older

Influenza | Vaccine

Japan
Astellas Pharma Inc

Completed

Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Astellas Pharma Global Development, Inc.

Terminated

A Study to Find a Suitable Dose of ASP8731 and Check for Medical Problems at Each Dose in Healthy Adults

Healthy Participants

United States
UMN Pharma Inc.

Completed

A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers

Healthy | Immunogenicity of ASP7374

Japan
Astellas Pharma Global Development, Inc.

Recruiting

A Study of ASP2074 in Adults With Solid Tumors

Advanced Solid Tumors

United States, Japan
Dana-Farber Cancer Institute
Astellas Pharma Inc; Regeneron Pharmaceuticals

Active, not recruiting

ASP8374 + Cemiplimab in Recurrent Glioma

Glioblastoma | Recurrent Glioblastoma

United States
Astellas Pharma Europe B.V.

Completed

A Study of ASP8302 in Participants With Underactive Bladder

Underactive Bladder

Japan, Poland, Germany, Netherlands, Slovakia, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

Healthy Subjects

United States
Astellas Pharma Inc

Completed

ASP8302 Single and Multiple Ascending Oral Dose Study in Non-elderly Healthy Japanese Subjects

Healthy Subjects

Japan
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Completed

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Taiwan, Portugal, Spain, United Kingdom, Italy, Canada, Japan
UMN Pharma Inc.

Completed

A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers

Healthy

Japan
Astellas Pharma Global Development, Inc.

Recruiting

A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease

Intraoperative Ureter Visualization | Abdominolpelvic Surgery

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery

Intraoperative Ureter Visualization | Abdominolpelvic Surgery

United States
Astellas Pharma Global Development, Inc.

Completed

A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well

Renal Impairment | Healthy Volunteers

United States, Japan
Astellas Pharma Inc

Terminated

A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery

Melanoma | Breast Cancer | Sentinel Lymph Node Biopsy

United States
Astellas Pharma Inc

Completed

A Study for Ureter Visualization, Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal Surgery

Laparoscopic/Minimally Invasive Colorectal Surgery

United States
Astellas Pharma Inc

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male Participants

Healthy Volunteers

Japan
Astellas Pharma Inc

Terminated

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations

Japan
Astellas Pharma Global Development, Inc.

Withdrawn

A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

Subjects With NSCLC With an EGFR Activating Mutation
UMN Pharma Inc.

Completed

Study of ASP7374, Cell-culture-derived Influenza Vaccine

Influenza | Vaccine

Japan
UMN Pharma Inc.

Completed

Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine

Influenza

Japan
Astellas Pharma Europe B.V.

Completed

A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety (MOBILE)

Neuropathic Pain | Post-Herpetic Neuralgia (PHN) | Painful Diabetic Peripheral Neuropathy (PDPN)

Czechia, Germany, Poland, United Kingdom
Astellas Pharma Global Development, Inc.

Withdrawn

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors

Solid Tumors | Epidermal Growth Factor Receptor (EGFR) Mutations
Astellas Pharma Inc

Terminated

An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer

Japan, Korea, Republic of, Taiwan
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor (EGFR) Mutations

United States
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males

Pharmacokinetics of ASP8477 | Pharmacodynamics of ASP8477

France, Belgium
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-Small-Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor Mutations

United States

Search clinical trials for: ASP8374

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations